Generic Name and Formulations:
Clobetasol propionate 0.05%; foam.
Indications for OLUX:
Treatment of plaque psoriasis of the scalp (moderate to severe) and non-scalp regions (mild to moderate).
≥12yrs: apply thin layer to affected area(s) twice daily; max 50g/week or 21 capfuls/week and 2 consecutive weeks' treatment per course. Discontinue when control is achieved. Wash hands after application. Do not occlude.
<12yrs: not recommended.
Not for oral, ophthalmic, or intravaginal use. Avoid use on face, axillae, groin, or other intertriginous areas. Do not use for diaper dermatitis or on pre-existing skin atrophy. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, reduce dose, or substitute with less potent corticosteroid if occurs. Increased risk of posterior subcapsular cataracts and glaucoma; monitor for visual symptoms. Treat infection if present; discontinue if infection persists or worsens. Avoid abrupt cessation in chronic use. Reevaluate periodically. Product is flammable. Pregnancy. Nursing mothers.
Burning, stinging, pruritus, erythema, skin atrophy, folliculitis, dermal cracking and fissuring, telangiectasia, striae; allergic contact dermatitis (discontinue if irritation occurs), HPA axis suppression (esp. in children); rare: Cushing's syndrome, hyperglycemia.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
- Patient Fears of Placebo Use in Clinical Trials
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|